Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome

Diabetes Research and Clinical Practice

Volumn 91, Issue 1, 2011, Pages 26-31

  Akinci, Baris ^a,b   Celtik, Aygul ^a   Yuksel, Faize ^c   Genc, Sinan ^a   Yener, Serkan ^a   Secil, Mustafa ^a   Ozcan, Mehmet Ali ^c   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c Division of Pediatric Hematology   (Turkey)

Author keywords

Cardiovascular risk; Metabolic syndrome; OPG; Previous gestational diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; OSTEOPROTEGERIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD LEVEL; BODY MASS; C REACTIVE PROTEIN BLOOD LEVEL; CARDIOVASCULAR RISK; CAROTID ARTERY; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OSTEOPROTEGERIN BLOOD LEVEL; PREGNANCY DIABETES MELLITUS; WAIST CIRCUMFERENCE;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES, GESTATIONAL; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OSTEOPROTEGERIN; PREGNANCY; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA; TURKEY;

EID: 78650549522     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.09.028     Document Type: Article

References (38)

1. Bentley-Lewis R. Late cardiovascular consequences of gestational diabetes mellitus. Semin Reprod Med 2009, 27:322-329.
2. Carpenter M.W. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007, 30(Suppl. 2):S246-S250.
3. Akinci B., Celtik A., Yener S., Yesil S. Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertil Steril 2009.
4. Reece E.A., Leguizamon G., Wiznitzer A. Gestational diabetes: the need for a common ground. Lancet 2009, 373:1789-1797.
5. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
6. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
7. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
8. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.
9. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
10. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
11. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas heart study). Am J Cardiol 2007, 99:513-518.
12. Akinci B., Demir T., Celtik A., Baris M., Yener S., Ozcan M.A., et al. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract 2008, 82:172-178.
13. Madarasz E., Tamas G., Tabak A.G., Speer G., Lakatos P., Kerenyi Z. Osteoprotegerin levels in women with prior gestational diabetes mellitus. Diabetes Care 2009, 32:e5.
14. Coustan D.R., Carpenter M.W. Detection and treatment of gestational diabetes. Clin Obstet Gynecol 1985, 28:507-515.
15. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005, 13:322-327.
16. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J.P., Dupuy A.M. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005, 28:2176-2180.
17. Golledge J., McCann M., Mangan S., Lam A., Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35:1636-1641.
18. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
19. Xiang G.D., Xu L., Zhao L.S., Yue L., Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006, 55:2126-2131.
20. Shargorodsky M., Boaz M., Luckish A., Matas Z., Gavish D., Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009, 204:608-611.
21. Kim S.M., Lee J., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 2005, 63:594-598.
22. Jung C.H., Lee W.Y., Kim S.Y., Jung J.H., Rhee E.J., Park C.Y., et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 2009.
23. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
24. Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006, 47:1850-1857.
25. Yaturu S., Rains J., Jain S.K. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008, 44:168-171.
26. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48:561-568.
27. Jorgensen G.M., Vind B., Nybo M., Rasmussen L.M., Hojlund K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol 2009, 161:95-101.
28. Xiang G.D., Sun H.L., Zhao L.S. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract 2007, 76:199-206.
29. Ugur-Altun B., Altun A. Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. Arch Med Res 2007, 38:891-896.
30. Golledge J., Leicht A.S., Crowther R.G., Glanville S., Clancy P., Sangla K.S., et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology 2008, 111:51-56.
31. Gannage-Yared M.H., Fares F., Semaan M., Khalife S., Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006, 64:652-658.
32. Nabipour I., Kalantarhormozi M., Larijani B., Assadi M., Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2009.
33. Mazziotti G., Amato G., Sorvillo F., Piscopo M., Rizzo M.R., Lalli E., et al. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Eur J Endocrinol 2006, 154:373-377.
34. Asanuma Y., Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007, 195:e135-e141.
35. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474.
36. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001, 21:1610-1616.
37. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
38. Van Campenhout A., Clancy P., Golledge J. Serum osteoprotegerin as a biomarker for vascular disease. Am J Cardiol 2007, 100:561.